Pharmacokinetic/pharmacodynamic (PK/PD) considerations in the management of Gram-positive bacteraemia

International Journal of Antimicrobial Agents

Volumn 36, Issue SUPPL. 2, 2010, Pages

  Scaglione, Francesco ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

Antimicrobial agents; Bloodstream infections; Pharmacodynamics; Pharmacokinetics

Indexed keywords

DALFOPRISTIN; DALFOPRISTIN PLUS QUINUPRISTIN; DAPTOMYCIN; LINEZOLID; OXACILLIN; QUINUPRISTIN; TEICOPLANIN; TIGECYCLINE; VANCOMYCIN;

ABDOMINAL INFECTION; ABSENCE OF SIDE EFFECTS; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; AREA UNDER THE CURVE; ARTICLE; BACTEREMIA; BACTERIAL ENDOCARDITIS; BACTERIAL PERITONITIS; BACTERIAL PNEUMONIA; BACTERIAL SKIN DISEASE; BACTERICIDAL ACTIVITY; CLINICAL TRIAL; COMMUNITY ACQUIRED PNEUMONIA; CONCENTRATION RESPONSE; CONTINUOUS INFUSION; CRITICALLY ILL PATIENT; DISTRIBUTION VOLUME; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFICACY; DRUG HALF LIFE; DRUG INTERMITTENT THERAPY; DRUG SAFETY; DRUG TISSUE LEVEL; ENTEROCOCCAL INFECTION; ENTEROCOCCUS FAECIUM; GRAM POSITIVE INFECTION; HUMAN; LOWER RESPIRATORY TRACT INFECTION; MAXIMUM PLASMA CONCENTRATION; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MINIMUM INHIBITORY CONCENTRATION; MONTE CARLO METHOD; NEUTROPENIA; NONHUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; SEPSIS; SEPTIC SHOCK; SOFT TISSUE INFECTION; STAPHYLOCOCCAL BACTEREMIA; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION; VANCOMYCIN RESISTANT ENTEROCOCCUS; VENTILATOR ASSOCIATED PNEUMONIA;

ANTI-BACTERIAL AGENTS; BACTEREMIA; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS;

EID: 78650204457     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2010.11.011     Document Type: Article

References (97)

1. J.L. Vincent, D.J. Bihari, P.M. Suter, H.A. Bruining, J. White, and M.H. Nicolas-Chanoin The prevalence of nosocomial infection in intensive care units in Europe. Results of the European Prevalence of Infection in Intensive Care (EPIC) Study. EPIC International Advisory Committee JAMA 274 1995 639 644
2. D.J. Weber, R. Raasch, and W.A. Rutala Nosocomial infections in the ICU: the growing importance of antibiotic-resistant pathogens Chest 115 Suppl. 3 1999 34S 41S
3. J.L. Vincent Nosocomial infections in adult intensive care units Lancet 361 2003 2068 2077
4. D.L. Paterson Restrictive antibiotic policies are appropriate in intensive care units Crit Care Med 31 Suppl. 1 2003 S25 S28
5. M.H. Kollef Optimizing antibiotic therapy in the intensive care unit setting Crit Care 5 2001 189 195
6. F. Scaglione, and L. Paraboni The influence of pharmacokinetic/ pharmacodynamic (PK/PD) of antibacterials in their dosing regimens selection Expert Rev Anti Infect Ther 4 2006 479 490
7. G.L. Drusano Antimicrobial pharmacodynamics: critical interactions of 'bug and drug' Nat Rev Microbiol 2 2004 289 300
8. W.A. Craig, and B. Suh Protein binding and the antimicrobial effects: methods for the determination of protein binding V. Lorian, Antibiotics in laboratory medicine 1991 Williams and Wilkins Baltimore 367 402
9. D. Andes, and W.A. Craig Animal model pharmacokinetics and pharmacodynamics: a critical review Int J Antimicrob Agents 19 2002 261 268
10. W.A. Craig Does the dose matter? Clin Infect Dis 33 Suppl. 2001 S233 S237
11. W.A. Craig Basic pharmacodynamics of antibacterials with clinical applications to the use of β-lactams, glycolpeptides and linezolid Infect Dis Clin North Am 17 2003 479 501
12. F. Pea, and P. Viale The antimicrobial therapy puzzle: could pharmacokinetic-pharmacodynamic relationships be helpful in addressing the issue of appropriate pneumonia treatment in critically ill patients? Clin Infect Dis 42 2006 1764 1771
13. G.L. Drusano Prevention of resistance: a goal for dose selection of antimicrobial agents Clin Infect Dis 36 Suppl. 1 2003 S42 S50
14. F.M.E. Wagenlehner, W. Weidner, and K.G. Naber Pharmacokinetic characteristics of antimicrobials and optimal treatment of urosepsis Clin Pharmacokinet 46 2007 291 305
15. F. Pea, and M. Furlanut Pharmacokinetic aspects of treating infections in the intensive care unit: focus on drug interactions Clin Pharmacokinet 40 2001 833 868
16. M. Pinder, R. Bellomo, and J. Lipman Pharmacological principles of antibiotic prescription in the critically ill Anaesth Intensive Care 30 2002 134 144
17. M.J. Weinbren Pharmacokinetics of antibiotics in burn patients J Antimicrob Chemother 44 1999 319 327
18. U. Jaehde, and F. Sorgel Clinical pharmacokinetics in patients with burns Clin Pharmacokinet 29 1995 15 28
19. J.A. Roberts, and J. Lipman Antibacterial dosing in intensive care: pharmacokinetics, degree of disease and pharmacodynamics of sepsis Clin Pharmacokinet 45 2006 755 773
20. C. Bartal, A. Danon, F. Schlaeffer, K. Reisenberg, M. Alkan, and R. Smoliakov Pharmacokinetic dosing of aminoglycosides: a controlled trial Am J Med 114 2003 194 198
21. A. Contrepois, V. Joly, L. Abel, B. Pangon, J.M. Vallois, and C. Carbon The pharmacokinetics and extravascular diffusion of teicoplanin in rabbits and comparative efficacy with vancomycin in an experimental endocarditis model J Antimicrob Chemother 21 1988 621 631
22. H.F. Chambers, and S. Kennedy Effect of dosage, peak and trough concentrations in serum, protein binding and bactericidal rate of efficacy of teicoplanin in a rabbit model of endocarditis Antimicrob Agents Chemother 34 1990 510 514
23. J.D. Knudsen, K. Fuursted, F. Espersen, and N. Frimodt-Moller Activities of vancomycin and teicoplanin against penicillin-resistant pneumococci in vitro and in vivo and correlation to pharmacokinetic parameters in the mouse peritonitis model Antimicrob Agents Chemother 41 1997 1910 1915
24. J.D. Knudsen, K. Fuursted, S. Raber, F. Espersen, and N. Frimodt-Møller Pharmacodynamics of glycopeptides in the mouse peritonitis model of Streptococcus pneumoniae or Staphylococcus aureus infection Antimicrob Agents Chemother 44 2000 1247 1254
25. J.M. Hyatt, P.S. McKinnon, G.S. Zimmer, and J.J. Schentag The importance of pharmacokinetic/pharmacodynamic surrogate markers to outcome: focus on antibacterial agents Clin Pharmacokinet 28 1995 143 160
26. P.A. Moise-Broder, A. Forrest, M.C. Birmingham, and J.J. Schentag Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections Clin Pharmacokinet 43 2004 925 942
27. E. Polard, V. Le Bouquin, P. Le Corre, C. Kérebel, H. Trout, and A. Feuillu Non steady state and steady state PKS Bayesian forecasting and vancomycin pharmacokinetics in ICU adult patients Ther Drug Monit 21 1999 395 403
28. M. Del Mar Fernández de Gatta Garcia, N. Revilla, M.V. Calvo, A. Domínguez-Gil, and A. Sánchez Navarro Pharmacokinetic/ pharmacodynamic analysis of vancomycin in ICU patients Intensive Care Med 33 2007 279 285
29. J.J. Schentag Antimicrobial management strategies for Gram-positive bacterial resistance in the intensive care unit Crit Care Med 29 Suppl. 4 2001 S100 S107
30. B. Byl, P. Clevenbergh, F. Jacobs, M.J. Struelens, F. Zech, and A. Kentos Impact of infectious diseases specialists and microbiological data on the appropriateness of antimicrobial therapy for bacteremia Clin Infect Dis 29 1999 60 66
31. M. Wysocki, F. Delatour, F. Faurisson, A. Rauss, Y. Pean, and B. Misset Continuous versus intermittent infusion of vancomycin in severe staphylococcal infections: prospective multicenter randomized study Antimicrob Agents Chemother 45 2001 2460 2467
32. A. Di Filippo, A.R. De Gaudio, A. Novelli, E. Paternostro, C. Pelagatti, and P. Livi Continuous infusion of vancomycin in methicillin-resistant staphylococcus infection Chemotherapy 44 1998 63 68
33. J. Rello, J. Sole-Violan, M. Sa-Borges, J. Garnacho-Montero, E. Muñoz, and G. Sirgo Pneumonia caused by oxacillin-resistant Staphylococcus aureus treated with glycopeptides Crit Care Med 33 2005 1983 1987
34. R.S. Slavik, and P.J. Jewesson Selecting antibacterials for outpatient parenteral antimicrobial therapy: pharmacokinetic-pharmacodynamic consideration Clin Pharmacokinet 42 2003 793 817
35. M.J. Rybak, B.M. Lomaestro, J.C. Rotscahfer, R.C. Moellering, A.W. Craig, and M. Billeter Vancomycin therapeutic guidelines: a summary of consensus recommendations from the Infectious Diseases Society of America, the American Society of Health-System Pharmacists, and the Society of Infectious Diseases Pharmacists Clin Infect Dis 49 2009 325 327
36. D.J. Stalker, and G.L. Jungbluth Clinical pharmacokinetics of linezolid, a novel oxazolidinone antibacterial Clin Pharmacokinet 42 2003 1129 1140
37. A. Adembri, S. Fallani, M.I. Cassetta, S. Arrigucci, A. Ottaviano, and P. Pecile Linezolid pharmacokinetic/pharmacodynamic profile in critically ill septic patients: intermittent versus continuous infusion Int J Antimicrob Agents 31 2008 122 129
38. C.R. Rayner, A. Forrest, A.K. Meagher, M.C. Birmingham, and J.J. Schentag Clinical pharmacodynamics of linezolid in seriously ill patients treated in a compassionate use program Clin Pharmacokinet 42 2003 1411 1423
39. A.P. MacGowan Pharmacokinetic and pharmacodynamic profile of linezolid in healthy volunteers and patients with Gram-positive infections J Antimicrob Chemother 51 Suppl. 2 2003 ii17 ii25
40. M.J. Gentry-Nielsen, K.M. Olsen, and L.C. Preheim Pharmacodynamic activity and efficacy of linezolid in a rat model of pneumococcal pneumonia Antimicrob Agents Chemother 46 2002 1345 1351
41. C.F. Dailey, C.L. Dileto-Fang, L.V. Buchanan, M.P. Oramas-Shirey, D.H. Batts, and C.W. Ford Efficacy of linezolid in treatment of experimental endocarditis caused by methicillin-resistant Staphylococcus aureus Antimicrob Agents Chemother 45 2001 2304 2308
42. C. Buerger, N. Plock, P. Dehghanyar, C. Joukhadar, and C. Kloft Pharmacokinetics of unbound linezolid in plasma and tissue interstitium of critically ill patients after multiple dosing using microdialysis Antimicrob Agents Chemother 50 2006 2455 2463
43. C. Jacqueline, E. Batard, L. Perez, D. Boutoille, A. Hamel, and J. Caillon In vivo efficacy of continuous infusion versus intermittent dosing of linezolid compared to vancomycin in a methicillin-resistant Staphylococcus aureus rabbit endocarditis model Antimicrob Agents Chemother 46 2002 3706 3711
44. L.M. Boak, C.R. Rayner, and R.L. Nation Pharmacokinetic/pharmacodynamic factors influencing emergence of resistance to linezolid in an in vitro model Antimicrob Agents Chemother 51 2007 1287 1292
45. M.J. Rybak, H.H. Houlihan, R.C. Mercier, and G.W. Kaatz Pharmacodynamics of RP 59500 (quinupristin-dalfopristin) administered by intermittent versus continuous infusion against Staphylococcus aureus-infected fibrin-platelet clots in an in vitro infection model Antimicrob Agents Chemother 41 1997 1359 1363
46. R.N. Jones, C.H. Ballow, D.J. Biedenbach, J.A. Deinhart, and J.J. Schentag Antimicrobial activity of quinupristin-dalfopristin (RP 59500, Synercid) tested against over 28,000 recent clinical isolates from 200 medical centers in the United States and Canada Diagn Microbiol Infect Dis 31 1998 437 451
47. E. Hershberger, J.R. Aeschlimann, T. Moldovan, and M.J. Rybak Evaluation of bactericidal activities of LY333328, vancomycin, teicoplanin, ampicillin-sulbactam, trovafloxacin, and RP59500 alone or in combination with rifampin or gentamicin against different strains of vancomycin-intermediate Staphylococcus aureus by time-kill curve methods Antimicrob Agents Chemother 43 1999 717 721
48. H.M. Lamb, D.P. Figgitt, and D. Faulds Quinupristin/dalfopristin: a review of its use in the management of serious Gram-positive infections Drugs 58 1999 1061 1097 (Pubitemid 30055047)
49. D.T. Bearden Clinical pharmacokinetics of quinupristin/dalfopristin Clin Pharmacokinet 43 2004 239 252
50. G.M. Eliopoulos Quinupristin-dalfopristin and linezolid: evidence and opinion Clin Infect Dis 36 2003 473 481
51. W. Craig, and S. Ebert Pharmacodynamic activities of RP 59500 in an animal infection model Abstracts of 33rd interscience conference on antimicrobial agents and chemotherapy, 17-20 Oct New Orleans 1993 [Abstract 470]
52. B. Fantin, R. Leclercq, Y. Merle, L. Saint-Julien, C. Veyrat, and J. Duval Critical influence of resistance to streptogramin B-type antibiotics on activity of RP 59500 (quinupristin-dalfopristin) in experimental endocarditis due to Staphylococcus aureus Antimicrob Agents Chemother 39 1995 400 405
53. J.R. Aeschlimann, and M.J. Rybak Pharmacodynamic analysis of the activity of quinupristin-dalfopristin against vancomycin-resistant Enterococcus faecium with differing MBCs via time-kill-curve and postantibiotic effect methods Antimicrob Agents Chemother 42 1998 2188 2192
54. C. Carbon Pharmacodynamics of macrolides, azalides, and streptogramins: effect on extracellular pathogens Clin Infect Dis 27 1998 28 32
55. D.L. Paterson Clinical experience with recently approved antibiotics Curr Opin Pharmacol 6 2006 486 490
56. R.D. Arbeit, D. Maki, F.P. Tally, E. Campanaro, and B.I. Eisenstein The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections Clin Infect Dis 38 2004 1673 1681
57. V.G. Fowler Jr., H.W. Boucher, G.R. Corey, E. Abrutyn, A.W. Karchmer, and M.E. Rupp Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus N Engl J Med 355 2006 653 665
58. S.T. Micek Alternatives to vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections Clin Infect Dis 45 Suppl. 3 2007 S184 S190
59. J.A. Silverman, L.I. Mortin, A.D. Vanpraagh, T. Li, and J. Alder Inhibition of daptomycin by pulmonary surfactant: in vitro modeling and clinical impact J Infect Dis 191 2005 2149 2152
60. S.K. Straus, and R.E.W. Hancock Mode of action of the new antibiotic for Gram-positive pathogens daptomycin: comparison with cationic antimicrobial peptides and lipopeptides Biochim Biophys Acta 1758 2006 1215 1223
61. C. Fenton, G.M. Keating, and M.P. Curran Daptomycin Drugs 64 2004 445 455
62. R. Akins, and M.J. Rybak Bactericidal activities of two daptomycin regimens against clinical strains of glycopeptide intermediate-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus faecium, and methicillin-resistant Staphylococcus aureus isolates in an in vitro pharmacodynamic model with simulated endocardial vegetations Antimicrob Agents Chemother 45 2001 454 459
63. A. Louie, P. Kaw, W. Liu, N. Jumbe, M.H. Miller, and G.L. Drusano Pharmacodynamics of daptomycin in a murine thigh model of Staphylococcus aureus infection Antimicrob Agents Chemother 45 2001 845 851
64. P.K. Dandekar, P.R. Tessier, P. Williams, C.H. Nightingale, and D.P. Nicolau Pharmacodynamic profile of daptomycin against Enterococcus species and methicillin-resistant Staphylococcus aureus in a murine thigh infection model J Antimicrob Chemother 52 2003 405 411
65. N. Safdar, D. Andes, and W.A. Craig In vivo pharmacodynamic activity of daptomycin Antimicrob Agents Chemother 48 2004 63 68
66. R. Cha, R.G. Grucz Jr., and M.J. Rybak Daptomycin dose-effect relationship against resistant Gram-positive organisms Antimicrob Agents Chemother 47 2003 1598 1603
67. S.Y. Lee, H.W. Fan, J.L. Kuti, and D.P. Nicolau Update on daptomycin: the first approved lipopeptide antibiotic Expert Opin Pharmacother 7 2006 1381 1397
68. G.L. French Bactericidal agents in the treatment of MRSA infections - the potential role of daptomycin J Antimicrob Chemother 58 2006 1107 1117
69. F.B. Oleson Jr., C.L. Berman, J.B. Kirkpatrick, K.S. Regan, J.J. Lai, and F.P. Tally Once-daily dosing in dogs optimizes daptomycin safety Antimicrob Agents Chemother 44 2000 2948 2953
70. K.L. Tedesco, and M.J. Rybak Daptomycin Pharmacotherapy 24 2004 41 57
71. F.P. Tally, M. Zeckel, M.M. Wasilewski, C. Carini, C.L. Berman, and G.L. Drusano Daptomycin: a novel agent for Gram-positive infections Expert Opin Invest Drugs 8 1999 1223 1238
72. B.H. Dvorchik, D. Brazier, M.F. DeBruin, and R.D. Arbeit Daptomycin pharmacokinetics and safety following administration of escalating doses once daily to healthy subjects Antimicrob Agents Chemother 47 2003 1318 1323
73. M.J. Rybak, P. McKinnon, R. Cha, and B.H. Dvorchik Daptomycin pharmacodynamics (PD) versus MRSA at various doses as assessed by a Monte Carlo prediction model Program and abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, 16-19 December 2001 Chicago, IL 2001 American Society for Microbiology Washington, DC [A-2195]
74. R. Cha, and M.J. Rybak Daptomycin against multiple drug-resistant Staphylococcus and Enterococcus isolates in an in vitro pharmacodynamic model with simulated endocardial vegetations Diagn Microbiol Infect Dis 47 2003 539 546
75. R.H. Drew Emerging options for treatment of invasive, multidrug-resistant Staphylococcus aureus infections Pharmacotherapy 27 2007 227 249
76. P.A. Bradford, D.T. Weaver-Sands, and P.J. Petersen In vitro activity of tigecycline against isolates from patients enrolled in phase 3 clinical trials of treatment for complicated skin and skin-structure infections and complicated intra-abdominal infections Clin Infect Dis 41 Suppl. 5 2005 S315 S332
77. D. Milatovic, F.J. Schmitz, J. Verhoef, and A.C. Fluit Activities of the glycylcycline tigecycline (GAR-936) against 1,924 recent European clinical bacterial isolates Antimicrob Agents Chemother 47 2003 400 404
78. E. Cercenado, S. Cercenado, J.A. Gomez, and E. Bouza In vitro activity of tigecycline (GAR-936), a novel glycylcycline, against vancomycin-resistant enterococci and staphylococci with diminished susceptibility to glycopeptides J Antimicrob Chemother 52 2003 138 139
79. M.D. Kitzis, A. Ly, and F.W. Goldstein In vitro activities of tigecycline (GAR-936) against multidrug-resistant Staphylococcus aureus and Streptococcus pneumoniae Antimicrob Agents Chemother 48 2004 366 367
80. W.E. Rose, and M.J. Rybak Tigecycline: first of a new class of antimicrobial agents Pharmacotherapy 26 2006 1099 1110
81. E.J. Ellis-Grosse, T. Babinchak, N. Dartois, G. Rose, and E. Loh The efficacy and safety of tigecycline in the treatment of skin and skin-structure infections: results of 2 double-blind phase 3 comparison studies with vancomycin-aztreonam Clin Infect Dis 41 Suppl. 5 2005 S341 S353
82. T. Babinchak, E. Ellis-Grosse, N. Dartois, G.M. Rose, and E. Loh The efficacy and safety of tigecycline for the treatment of complicated intra-abdominal infections: analysis of pooled clinical trial data Clin Infect Dis 41 Suppl. 5 2005 S354 S367
83. P.J. Petersen, N.V. Jacobus, W.J. Weiss, P.E. Sum, and R.T. Testa In vitro and in vivo antibacterial activities of a novel glycylcycline, the 9-t-butylglycylamido derivative of minocycline (GAR-936) Antimicrob Agents Chemother 43 1999 738 744
84. P.J. Petersen, P. Labthavikul, C.H. Jones, and P.A. Bradford In vitro antibacterial activities of tigecycline in combination with other antimicrobial agents determined by chequerboard and time-kill analysis J Antimicrob Chemother 57 2006 573 576
85. H. Ziglam Daptomycin and tigecycline: a review of clinical efficacy in the antimicrobial era Expert Opin Pharmacother 8 2006 2279 2292
86. A.K. Meagher, P.G. Ambrose, T.H. Grasela, and E.J. Ellis-Grosse The pharmacokinetic and pharmacodynamic profile of tigecycline Clin Infect Dis 41 Suppl. 5 2005 S333 S340
87. K.N. Agwuh, and A. MacGowan Pharmacokinetics and pharmacodynamics of the tetracyclines including glycylcyclines J Antimicrob Chemother 58 2006 256 265
88. M.L. van Ogtrop, D. Andes, T.J. Stamstad, B. Conklin, W.J. Weiss, and W.A. Craig In vivo pharmacodynamic activities of two glycylcyclines (GAR-936 and WAY 152,288) against various Gram-positive and Gram-negative bacteria Antimicrob Agents Chemother 44 2000 943 949
89. A.K. Meagher, P.G. Ambrose, T.H. Grasela, and E.J. Ellis-Grosse Pharmacokinetic/pharmacodynamic profile for tigecycline - a new glycylcycline antimicrobial agent Diagn Microbiol Infect Dis 52 2005 165 171
90. A.K. Meagher, J.A. Passarell, B.B. Cirincione, S.A. Van Wart, K. Liolios, and T. Babinchak Exposure-response analyses of tigecycline efficacy in patients with complicated skin and skin-structure infections Antimicrob Agents Chemother 51 2007 1939 1945
91. J.A. Passarell, A.K. Meagher, K. Liolios, B.B. Cirincione, S.A. Van Wart, and T. Babinchak Exposure-response analyses of tigecycline efficacy in patients with complicated intra-abdominal infections Antimicrob Agents Chemother 52 2008 204 210
92. T.L. Doan, H.B. Fung, D. Mehta, and P.F. Riska Tigecycline: a glycylcycline antimicrobial agent Clin Ther 28 2006 1079 1106
93. T. Glück, and S.M. Opal Advances in sepsis therapy Drugs 64 2004 837 859
94. H. Lode Management of serious nosocomial bacterial infections: do current therapeutic options meet the need? Clin Microbiol Infect 11 2005 778 787
95. F. Scaglione Can PK/PD be used in everyday clinical practice Int J Antimicrob Agents 19 2002 349 353
96. M.M. Fernandez de Gatta, I. Fruns, and A. Dominguez-Gil Individualizing vancomycin dosing regimens: an evaluation of two pharmacokinetic dosing programs in critically ill patients Pharmacotherapy 14 1994 196 201
97. T. Gauthier, B. Lacarelle, F. Marre, P.H. Villard, J. Catalin, and A. Durand Predictive performance of two software packages (USC*- PACK PC and Abbott PKS system) for the individualization of amikacin dosage in intensive care unit patients Int J Biomed Comput 36 1994 131 134